Riskpilot← Back to searchSign inGet full accessLinnane Pharma AB
ABActiveOrg 5569494346Möllarevägen 10Activities of holding companies · NACE 6421Est. 20132 employees
Revenue 2025
SEK 5,7M
+6% vs 2024
EBITDA margin
47.8%
+3% vs 2024
Equity ratio
79.0%
Financial strength
Net profit 2025
SEK 1,3M
-89% vs 2024
| Revenue | SEK 5,7M | +6% |
| EBITDA | SEK 2,7M | +3% |
| Net profit | SEK 1,3M | -89% |
| Total assets | SEK 82M | +1% |
| Equity | SEK 64,8M | +2% |
| Employees | 2 | — |
Legal name
Linnane Pharma AB
Org number
5569494346
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
19 november 2013
Share capital
SEK 500 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Svanborg, Marianne Catharina
Company purpose
Aktiebolaget ska bedriva och främja forskning, utveckling och försäljning av produkter inom det medicinska området och andra hälsorelaterade områden genom egen verksamhet, som konsult eller genom intressebolag ävensom idka därmed jämförlig verksamhet samt äga och förvalta aktier och andra värdepapper.
Address
Möllarevägen 10
Email
jakob.testad@linnanepharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 539 | 1 226 | 987 | 2 123 | 3 900 | 4 300 | 5 358 | 5 658 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 207 | 74 | −88 | 330 | −89 | −5 | 2 046 | 1 753 | 2 633 | 2 706 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 207 | 74 | −88 | 330 | −89 | −5 | 2 046 | 1 753 | 2 633 | 2 706 |
| Net financials | — | — | — | 25 | −59 | −97 | −1 044 | 8 852 | 9 627 | −591 |
| Profit before tax | 171 | 49 | −88 | 271 | −149 | 43 | 753 | 10 454 | 11 810 | 1 584 |
| Tax | −23 | −21 | −0 | −61 | −3 | −2 | −157 | −100 | −283 | −331 |
| Net profit | 148 | 28 | −88 | 210 | −152 | 41 | 596 | 10 354 | 11 527 | 1 253 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 037 | 2 066 | 1 795 | 2 328 | 5 386 | 46 992 | 70 920 | 77 192 | 81 387 | 82 005 |
| Equity | 985 | 1 013 | 925 | 1 134 | 983 | 41 024 | 41 620 | 51 974 | 63 502 | 64 755 |
| Long-term debt | 0 | 0 | 0 | 0 | 3 200 | 3 200 | 26 027 | 20 170 | 13 638 | 12 425 |
| Short-term debt | 1 017 | 993 | 810 | 1 049 | 1 058 | 2 767 | 3 023 | 4 647 | 3 397 | 3 445 |
| Total debt | 1 017 | 993 | 810 | 1 049 | 4 258 | 5 967 | 29 050 | 24 817 | 17 035 | 15 870 |
EBITDA margin
47.8%
This company
15.8%
Market median
+203% vs market
20162025
Equity ratio
79.0%
This company
38.2%
Market median
+107% vs market
20162025
Return on equity
1.9%
This company
18.4%
Market median
-90% vs market
20162025
Net profit margin
22.1%
This company
8.1%
Market median
+173% vs market
20162025
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20162025
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HT Chief Auditor | Chief Auditor | 2020 | — | — |
PA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Linnane Pharma AB (this company)
Hamlet BioPharma ABBoard members of Linnane Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Thomas Peter Jönsson | Chief Auditor | 0 companies |
| Per Anders Jakob Testad | Chief Executive Officer | 0 companies |
| Anders Jerker Wihlborn | Board of Directors | 0 companies |
| Per Olof Bertil Gunnesson | Board of Directors | 0 companies |
| Ines Marie Adeline Ambite | Board of Directors | 0 companies |
| Nils Petter M Segelman Lindqvist | Board of Directors | 0 companies |
| Göran Henrik Mikael Streiffert | Board of Directors | 0 companies |
| Marianne Catharina Svanborg | Chairman | 0 companies |
| Gustav Staffan Svanborg Edén | Deputy Board Member | 0 companies |
| Nils Bill Stefan Hansson | Board of Directors | 0 companies |
| Jan Gustaf Zetterberg | Board of Directors | 0 companies |